Company news

Annexon, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

October 14, 2024

Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress

September 8, 2024

Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio

September 2, 2024

Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

August 11, 2024

Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy

August 4, 2024

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

July 10, 2024

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

June 24, 2024

Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting

June 17, 2024

Annexon Announces Pricing of $125 Million Underwritten Public Offering

June 4, 2024

Annexon Announces Proposed Public Offering of Common Stock

June 3, 2024

Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome

June 3, 2024

Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

June 2, 2024

Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

May 12, 2024

Annexon Biosciences to Present at the Bank of America Health Care Conference

May 8, 2024

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

May 6, 2024

Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting

April 30, 2024

Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

April 2, 2024

Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones

March 25, 2024

Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference

February 26, 2024

Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach

February 20, 2024

Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases

January 6, 2024

Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 26, 2023

Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway

December 19, 2023

Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint

December 19, 2023

Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock

December 19, 2023

Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

November 21, 2023

Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results

November 12, 2023

Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference

November 8, 2023

Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy

October 23, 2023

Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)

October 9, 2023

Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference

September 18, 2023

Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results

August 6, 2023

Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy

July 29, 2023

Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer

July 26, 2023

Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023

July 23, 2023

Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function

May 23, 2023

Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress

May 7, 2023

Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference

April 10, 2023

Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones

March 5, 2023

Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference

February 26, 2023

Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises

January 7, 2023

Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio

January 5, 2023

Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023

November 2, 2022

Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025

July 10, 2022

Annexon Announces $130 Million Private Placement Financing

July 7, 2022

Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’s Disease

June 6, 2022

Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results

May 8, 2022

Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy

April 6, 2022

Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntington’s Disease at AAN 2022

March 2, 2022

Annexon Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results

February 28, 2022

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 23 decks. Every deck is listed under its year.